Prognostic value of interim FDG-PET in diffuse large cell lymphoma:
results from the CALGB 50303 Clinical Trial
- Citation:
- Blood vol 135 (25) 2224-2234
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 9
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180850, UG1CA189960
- Corr. Author:
- Authors:
- Heiko Schöder Mei-Yin C. Polley Michael V. Knopp Nathan Hall Lale Kostakoglu Jun Zhang Howard R. Higley Gary Kelloff Heshan Liu Andrew D. Zelenetz Bruce D. Cheson Nina Wagner-Johnston Brad S. Kahl Jonathan W. Friedberg Eric D. Hsi John P. Leonard Lawrence H. Schwartz Wyndham H. Wilson Nancy L. Bartlett
- Networks:
- CAPITAL, LAPS-MD017, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, NY018, PA121, VA009
- Study
- CALGB-50303
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-580603
- Phases:
- 3, 3
- Keywords:
- 8, 39, Clinical Trials and Observations